Table 1 Demographic and clinical characteristics of SONFH patients and AONFH patients

Number of patients

32

36

Gender (male/female)

12/20

21/15

0.086

Age (years)

45.91 ± 15.75

50.17 ± 12.68

0.074

3.29

BMI (kg/m2)

24.42 ± 4.08

25.91 ± 2.55

0.022

5.47

Smoker n (%)

13(40.63%)

22(61.11%)

0.092

Diabetes

1

3

0.616

Hypertension

4

4

1.000

Characteristics of ONFH

Number of hips

61

63

Side (right: left)

31:30

31:32

0.857

0.03

Timing since the onset of the ONFH, months

53.25 ± 75.44

60.28 ± 65.46

0.854

0.03

Harris score

VAS score

Steroid dosage

Steroid pulse therapy, n (%)

16(50.00%)

NA

NA

Duration of Steroid administration, years

4.78 ± 6.54

NA

NA

Steroid treatment

Drug species

Prednisone

NA

NA

Methylprednisolone

NA

NA

Dexamethasone

NA

NA

Alcohol consumption

Duration of alcohol consumption (years)

NA

24.67 ± 11.47

NA

Weekly ethanol consumption (g/week)

NA

2412.50 ± 1435.09

NA

Ethanol drink-years ((g/week) × years)

NA

59020.83 ± 45448.25

NA

ARCO STAGE

0.185

Non-osteonecrosis

3

9

STAGE I

9

7

STAGE II

7

6

STAGE IIIA

7

5

STAGE IIIB

13

25

STAGE IV

25

20